期刊
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
卷 37, 期 1, 页码 1724-1736出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14756366.2022.2086867
关键词
Alzheimer's disease; GSK-3 beta inhibitors; A beta; tau hyperphosphorylation; neurite outgrowth
资金
- key research and development program of Shandong province [2019GSF108045]
A series of novel thieno[3,2-c]pyrazol-3-amine derivatives were designed and synthesized as potential GSK-3 beta inhibitors, among which 16b was identified as a potent inhibitor. At the cellular level, 16b showed no toxicity and effectively promoted neuronal differentiation and neurite outgrowth.
Glycogen synthase kinase 3 beta (GSK-3 beta) catalyses the hyperphosphorylation of tau protein in the Alzheimer's disease (AD) pathology. A series of novel thieno[3,2-c]pyrazol-3-amine derivatives were designed and synthesised and evaluated as potential GSK-3 beta inhibitors by structure-guided drug rational design approach. The thieno[3,2-c]pyrazol-3-amine derivative 16b was identified as a potent GSK-3 beta inhibitor with an IC50 of 3.1 nM in vitro and showed accepted kinase selectivity. In cell levels, 16b showed no toxicity on the viability of SH-SY5Y cells at the concentration up to 50 mu M and targeted GSK-3 beta with the increased phosphorylated GSK-3 beta at Ser9. Western blot analysis indicated that 16b decreased the phosphorylated tau at Ser396 in a dose-dependent way. Moreover, 16b effectively increased expressions of beta-catenin as well as the GAP43, N-myc, and MAP-2, and promoted the differentiated neuronal neurite outgrowth. Therefore, the thieno[3,2-c]pyrazol-3-amine derivative 16b could serve as a promising GSK-3 beta inhibitor for the treatment of AD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据